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A B S T R A C T
This work deals with the antisolvent crystallization of LASSBio-294 (3,4-methylenedioxybenzoyl-2-thienylhy-
drazon) assisted by ultrasound. An ionic liquid (IL), 1-ethyl-3-methylimidazolium methyl phosphonate [emim]
[CH3O(H)PO2] was used as solvent and water as antisolvent. The inﬂuence of the following parameters on
crystals properties (size distribution, morphology, residual solvent and in vitro dissolution) were studied with
two mixing mode (quick and dropwise) of solution with antisolvent. The impact of washing and drying process
was also evaluated. Comparative studies of conventional crystallization conditions (without ultrasound) were
also performed. The eﬀect of ultrasound on LASSBio-294 recrystallized properties was inﬂuenced by the add
mode, water/IL ratio and drug solution concentration. As example, US promoted the formation of small crystals
with high residual IL under the following conditions: quick addition, high drug solution concentration and high
water/IL ratio. However, despite the decrease of elementary particle size, ultrasound did not avoid crystals
agglomeration. The drug dissolution rate was aﬀected by the physical structure of agglomerates. When employed
as drying process of washed crystals, spray drying reduced this agglomeration and improved the dissolution of
LASSBio-294 crystals.
1. Introduction
LASSBio-294, 3,4-Methylenedioxybenzoyl-2-thienylhydrazone is a
drug candidate for the treatment of cardiac failure and prevention of
myocardial infarction induced by cardiac dysfunction [1,2]. Since
LASSBio-294 integrates the category of the poorly water-soluble drugs,
its bioavailability could be limited.
Poor aqueous solubility of a drug entity can be addressed with
various pharmaceutical particle technologies, among them, the mod-
iﬁcation of drug crystal properties like reduction of particle size within
microscale or to nanoscale [3].
Antisolvent crystallization is an eﬀective way to prepare micro or
nano-sized drug particles. The technique involves the mixing of two
miscible ﬂuids: the drug dissolved in a solvent and an antisolvent,
which reduces the drug solubility in the solvent, causing the drug to
crystallize out of the solution. The mixing generates high super-
saturation that favors nucleation and then the formation of small
crystal. The properties of the ﬁnal crystalline product such as size,
morphology and purity are signiﬁcantly dependent on the rate,
magnitude and uniformity of the supersaturation generated during this
process [4]. Poor mixing between drug solution and antisolvent leads to
accidental zones of supersaturation, heterogeneous growth of crystals
aﬀecting the particle size and morphological features.
One technical requirement associated with this crystallization
technique is a reasonable solubility of the drug in the solvent. A large
part of pipeline drug entities lacks suﬃcient solubility in organic sol-
vents typically used for recrystallization, as ethanol. To overcome this
problem, supercritical ﬂuids and ionic liquids are some of the alter-
native solvents which have been currently tested as good solvents for
drugs poorly soluble in traditional volatile organic solvents [5].
Ionic liquids (IL) are deﬁned as salts composed of separate cations
and anions with melting points below 100 °C. In general, they are
thermally stable, nonﬂammable and exhibit very low vapor pressure.
The particular use of ILs as solvents for pharmaceutical drugs has been
described [6–11]. Few studies in the literature deals with the use of ILs
as solvents for drug crystallization purposes [11–14] and diﬀerent ef-
fects on the ﬁnal products were reported, for instance, the production of
ultraﬁne amorphous particles of rifampicin [15] or the obtention of
⁎ Corresponding author.
E-mail addresses: jacqueline.resende-de-azevedo@univ-lyon1.fr (J. Resende de Azevedo), fabienne.espitalier@mines-albi.fr (F. Espitalier),
maria-ines.re@mines-albi.fr (M.I. Ré).
1 Current address.
?
new polymorphs of adefovir dipivoxil [16,17].
Our group has previously reported promising results of solubility of
LASSBio-294 in seven imidazolium based ionic liquids miscible or
partially miscible with water (1-ethyl-3-methylimidazolium methyl
phosphonate [emim][CH3(H)PO2, 1-ethyl-3-methylimidazolium ethyl
phosphonate [emim][CH3CH2O(H)PO2], 1-ethyl-3-methylimidazolium
acetate [emim][CH3OO], 1,3-dimethylimidazolium methyl phospho-
nate [dmim][CH3O(H)PO2], 1-butyl-3-methylimidazolium acetate
[bmim][CH3OO], 1-butyl-3-methylimidazolium tetraﬂuoroborate
[bmim][BF4] and 1-butyl-3-methylimidazolium bis(tri-
ﬂuoromethanesulfonyl)imide [bmim][NTf2] [18]. Interactions such as
hydrogen bonds, van der Waals forces and π-π-solvent-solvent inter-
actions permitted to explain the diﬀerence of solubility observed.
In addition LASSBio-294 antisolvent crystallization was performed
using 1-ethyl-3-methylimidazolium methyl phosphonate [emim]
[CH3(H)PO2] as solvent and water as antisolvent was performed
[12,19]. In this study, pre-mixer was used to mix the drug/solvent so-
lution and the anti-solvent. The results revealed that the intense mixing
promote with pre-mixers at high solute concentration (159mg·g−1 so-
lution) seemed to favor the formation of smaller crystals more than
without pre-mixer. However, the formation of a gel phase was observed
in some operating conditions. Nevertheless, the amount of residual
solvent was lower without pre-mixer allowing a better deﬁnition of
crystals edges.
In the present study, the crystallization was conducted in a stirred
vessel without pre-mixer in order to minimize the residual ionic liquid
in crystals. Application of ultrasound is known to provide uniform
mixing conditions throughout the vessel during antisolvent process.
Indeed, ultrasound intensiﬁes the mass transfer when it propagates
through a liquid medium due to the formation of cavitation bubbles.
These eﬀects bring considerable beneﬁts to crystallization processes,
such as rapid induction of primary nucleation, reduction of crystal size,
inhibition of agglomeration and manipulation of crystal size distribu-
tion [20]. Reports about ILs-based processes assisted by ultrasound
have been described for synthesis of Bi2S3 nanoparticles [21], quino-
lines [22] and imidazolium salts [23]. These studies have motivated the
investigation of the ultrasound eﬀect during LASSBio-294 crystal-
lization. The inﬂuence of the following parameters on crystals proper-
ties (size distribution, morphology, residual solvent and in vitro dis-
solution) was investigated: the add mode (quick and dropwise) of the
solution into the vessel, the LASSBio-294 concentration in the solution,
the water/IL mass ratio and the ultrasound power. The eﬀect of
washing and drying methods was also evaluated. Experiments without
ultrasound was conducted for comparison.
2. Experimental section
2.1. Materials
The LASSBio-294 was obtained from Cristália Ltda (Itapira, SP,
Brazil) and used without further puriﬁcation. It is in the form of a
yellowish solid with a molecular weight of 274.3 g·mol−1 and 99.96%
wt purity. The ionic liquid, 1-ethyl-3-methylimidazolium methyl
phosphonate ([emim][CH3O(H)PO2]), was obtained from Solvionic
(Toulouse, France) and it was used as received (> 98% pure). Sodium
dodecyl sulfate (SDS) was supplied by VWR International (Leuven,
Belgium) for in vitro dissolution. HPLC grade acetonitrile (Scharlau SL,
Spain), methane sulfonic acid (MSA) (Fluka, Buchs, Switzerland) for ion
chromatography were used to prepare the mobile phases. Sodium di-
hydrogen phosphate (NaH2PO4) (Sigma-Aldrich, Gillingham-Dorset,
England) and sodium hydrogen phosphate (Na2HPO4) (Alfa Aesar,
Karlsruhe, Germany) of analytical grade were used to prepare the
Fig. 1. Experimental set-up and process steps for LASSBio-294 antisolvent crystallization studies.
buﬀers and mobile phases. Water was distilled and puriﬁed using Milli-
Q Water Puriﬁcation System (Purelab Classic DI MK2, Elga, UK).
2.2. Crystallization method
LASSBio-294 solution at deﬁned concentration (29, 57 or
159mg·g−1 solution) was prepared in [emim][CH3O(H)PO2] as solvent
at 303.15 ± 0.5 K. The antisolvent (water) was introduced into a 0.2 L
glass vessel (diameter 6.3 cm) with double jacket equipped with a
mechanical turbine stirrer with 8 blades mounted on ﬂat disc
throughout the operation. The temperature at 298.15 ± 0.5 K was
controlled by a water bath (Julabo VC F30). Agitation at 800 rpm was
powered using a mechanical stirrer (Eurostar IKA labortechnick 2000
motor). Based on preliminary tests and solid-liquid equilibrium of our
ternary system, mass ratios water/[emim][CH3O(H)PO2] between 3.7
and 14.9 were used [19]. These mass ratios permit to maximize the
crystals yield. Two modes for mixing drug solution and antisolvent
were employed: quick (injection time equal to 50 s) and dropwise (in-
jection time between 20 and 22min) using an infusion pump (Harvard
PHD 2000 Infusion, USA). Ultrasound (SINAPTEC, Lezennes, France)
was used during the solution addition. The frequency of ultrasound was
20 kHz and dissipated power was ranged between 10 and 40W (Fig. 1).
As soon addition was over the suspension was stirred for 30min at
atmospheric pressure and 298.15 K then ﬁltered (pore size 0.2 μm,
polypropylene, Millipore, Bedford, MA, UK), and washed with water
(500 g, method 1) to remove the residual solvent. The particle size
distribution of the washed solids was measured by laser granulometry.
Crystals were then dried in vacuum oven (Heraeus Vacutherm-VT-
6025) at 323.15 K for 3–5 days and then further characterized (size,
crystalline structure, morphology, residual solvent and in vitro dis-
solution). All experimental conditions are given in Table 1.
2.3. Optimization of the washing process
In order to reduce the crystals residual solvent, two new washing
methods were tested (methods 2 and 3) with products of experiment 5.
In both cases, washing was performed in four steps with 1000 g of
water, doubling its amount from the method 1. In method 2, 250 g of
water were added directly into the ﬁltration system and mixed with the
crystals. Once the ﬁltration was ﬁnished, 250 g of water were added
again, then twice more. In method 3, each mixture of wet crystals with
water (250 g) was kept under magnetic stirring for 10min before ﬁl-
tration process.
2.4. Optimization of the drying process
To reduce observed crystals agglomeration during drying in oven,
spray drying was applied as an alternative drying method. Four addi-
tional experiments were then performed as replicates of experiments 5
and 9 (with ultrasound) and 6 and 10 (without ultrasound). After the
washing process, the crystals obtained were re-dispersed in pure water.
The new aqueous dispersions were then spray-dried with a 0.7 mm two-
ﬂuid pressurized atomizer at a feed rate of 2 g·min−1 in a laboratory-
scale mini spray dryer (Büchi Mini Spray-dryer B-290, Switzerland).
The atomizing air ﬂow rate was 500–600 NL·h−1. The inlet temperature
was controlled at 383.15 ± 5 K and the outlet temperature
(363.15 ± 5 K) was determined by the inlet temperature and relative
factors such as air and liquid ﬂow rates.
2.5. Characterization
2.5.1. Particle size
Mean particle size and particle size distribution were determined by
laser diﬀraction using a Mastersizer 3000 (Malvern Instruments. UK).
Raw LASSBio-294 and recrystallized samples (washed wet and dry
crystals) were adequately dispersed in distilled water before each
measurement. A few drops of suspension were added directly into the
tank of the laser diﬀractometry containing water until the desired range
(5–15%) of laser obscuration level was reached. A refractive index of
1.520 was used for the particles (by default use) and 1.33 for the
continuous phase (water). The samples circulated in the measuring cell
using the instrument’s internal stirring system (2200 rpm). Results were
expressed as number or volume percentage (%) according to the par-
ticle size diameter (μm). The mean surface diameter, D3,2, and mean
volume diameter, D4,3, calculations were done by using the Malvern
3000 software version 3.20 supplied by the manufacturer (Malvern
Instruments Ltd.).
2.5.2. Scanning electron microscopy (SEM)
The morphology of powder samples was visualized using an
Environmental Scanning Electron Microscope-Field Emission Gun mi-
croscope (Philips XL30 FEG, ESEM-FEG, FEI Company). The samples
were ﬁxed on an SEM stub using double-sided adhesive tape and coated
with platinum using a Polaron SC7640 high resolution SEM sputter
coater (Quorom Technologies, England). Images were taken with an
accelerating voltage of 20 kV.
Table 1
Summary of experimental conditions and results of the characterization of products.
Experiment number Concentration (mg·g−1 solution) Water/IL ratio Power of ultrasound (W) S* D4.3 (μm) D3.2 (μm) Residualsolvent (ppm)
Quick addition
1 159 13.9 0 14,918 14.0 3.0 6920
2 159 14.9 40 14,687 0.6 0.5 29,904
3 159 3.7 0 9099 2.6 0.8 12,055
4 159 3.9 40 9470 10.8 2.0 45,674
5 57 4.7 0 3715 4.0 1.3 18,240
6 57 4.7 40 3680 4.0 1.2 1176
Dropwise addition
7 57 13.3 0 4859 7.0 2.0 984
8 57 13.1 40 4871 1.8 0.8 933
9 57 4.6 0 3640 7.4 2.5 1265
10 57 4.6 40 3633 2.4 1.1 956
11 159 4.5 40 11,011 2.3 1.3 13,273
12 29 4.7 40 1851 2.3 1.1 887
13 57 4.6 30 3636 1.7 0.8 904
14 57 4.9 20 3918 1.8 0.9 1414
15 57 4.7 10 3678 6.8 2.7 9517
* Maximal supersaturation ratio=Ci/Ceq.
2.5.3. X-ray diﬀractometry (XRD)
The samples were analysed by XRD diﬀractometry (Philips X’Pert
diﬀractometer, PanAlytical, USA). The measurements were performed
using CuKα radiation at a scanning rate of 0.018° min−1 from 8 to 40°,
applying 45 kV and 40mA. The diﬀraction patterns were collected in an
angular range of 10–35°-2θ.
2.5.4. Speciﬁc surface area
The speciﬁc surface area was measured in a Surface Area Analyzer
and Porosity Analyser (Tristar II 3020, Micromeritics Instruments Co.,
USA) using the nitrogen adsorption method. In this method, calculation
was based on the BET equation. Before measuring, the sample powders
were degassed.
2.5.5. Residual solvent
A Dionex model ICS-3000 ion chromatograph was applied to de-
termine the residual solvent amount in the crystals by the quantiﬁca-
tion of cation-IL. This system consists of an autosampler, a degasser,
pumps and conductometric detector. A Dionex suppressor LERS 500
(4mm) for chemical suppression was installed between the conducto-
metric detector and the Dionex IonPac CS17 analytical column
(250mm× 4mm). A Dionex IonPac CG17 (50mm× 4mm) guard
column was also installed. The samples were eluted by isocratic elution
with acetonitrile-MSA 20mM mixtures (20:80 (w/w)) at a ﬂow rate of
1.0 mL·min−1. An injection volume of 25 μL was used. All chromato-
graphic analyses were carried at 308.15 ± 0.5 K. Cation-IL con-
centration in the crystals was determined from solutions prepared with
100% acetonitrile. The concentrations were calculated with linear re-
gression equation (Peak area (μS·min)= 0.0165C (μg·g−1 solu-
tion)− 0.0495, R2=0.9954) obtained with the linear ranges of cali-
bration curve between peak area and the concentration (0.6–144 μg·g−1
solution).
2.5.6. Dissolution test
Dissolution studies were performed using an Erweka DT60 dis-
solution apparatus (Erweka, Germany), according to the paddle method
(USP) and under sink-conditions (maximal concentration 15 µg/mL,
which is, lower than the third of the equilibrium concentration). The
stirring speed used was 50 rpm, and the temperature was maintained at
310.15 K ± 0.5 K (n=3). The dissolution medium (900 g) was phos-
phate buﬀer pH 7.4 containing SDS 0.5%. The phosphate buﬀer con-
sisted of a mixture 1.2% sodium dihydrogen phosphate (NaH2PO4) and
8.8% sodium hydrogen phosphate (Na2HPO4). Samples were taken at
appropriate time intervals. Samples were ﬁltered through a 0.2 μm ﬁlter
(Acrodisc GHP, Millipore, Bedford, MA, UK) and analyzed by HPLC.
The HPLC analyses were carried with a system consisted of an Agilent
chromatograph (Model 1100 series) equipped with a UV–Vis detector.
A reversed phase analytical Symmetry® C18 column, 100 Å, 5 μm
(4.6mm× 250mm, WAT054275, Waters) was maintained at room
temperature and equilibrated with the analytical mobile phase before
injection. The mobile phase consisted of a mixture of 20% acetoni-
trile and 80% phosphate buﬀer (0.02mol NaH2PO4/L with phosphoric
acid 1%, pH 4.5). The ﬂow rate was 1.0 μm3·min−1, the elution was
monitored at 318 nm, and the injection volume was 0.02 cm3. The
concentrations were calculated from a linear regression equation (Peak
area (mAU·s)= 61.971C (μg·g−1 solution)− 15.129, R2= 0.9990)
within the linear range of the calibration curve (0.6–81 μg·g−1 solu-
tion). The percentage of the dissolved drug for a given time was cal-
culated from the ratio between LASSBio-294 dissolved mass and
LASSBio-294 initial mass.
3. Results and discussion
3.1. Eﬀect of ultrasound on crystallization by quick addition
Table 1 summarizes all experimental conditions of crystallization by
quick addition tests performed without (experiments 1, 3 and 5) and
with ultrasound (experiments 2, 4 and 6). The inﬂuence of ultrasound
was studied at high drug solution concentration (159mg·g−1 solution,
experiments 2 and 4) and diﬀerent W/IL ratios. Experiments at low
drug solution concentration and W/IL ratio was also performed
(57mg·g−1 solution, experiment 6). Tests in silent condition were
performed for comparison.
Fig. 2 shows the particle size distributions of wet crystals obtained
by quick addition. As it can be seen, with high drug solution con-
centration and W/IL ratio, ultrasound promoted the formation of the
small crystals; the intensity of the ﬁrst peak (< 1 μm) is greater. The
mean volume diameter D4,3 of the wet crystals changed from 14.1 µm in
silent condition to 0.6 µm with ultrasound. At low W/IL ratio, the ap-
plication of ultrasound led to particles agglomeration and increased
D4,3 of wet crystals (from 2.6 µm to 10.8 µm). This indicates that, with
low W/IL ratio, smaller crystals were generated in silent conditions. In
both cases, the application of ultrasound increased the residual solvent
(6920 against 29904 ppm with high W/IL ratio; 12,055 against
45674 ppm with low W/IL ratio). However, with low concentration and
low W/IL ratio, ultrasound favored the generation of small crystals and
decreased residual solvent amounts (18240 ppm against 1176 ppm). In
all cases, it could be observed that the application of ultrasound mod-
iﬁed the morphology, making more uniform crystals with a rod-shape
excepted at high W/IL ratio and high initial drug solution concentration
(Fig. 3).
3.2. Eﬀect of ultrasound on crystallization by dropwise addition
After the study with quick addition, the drug solution was in-
troduced in the antisolvent phase by dropwise mode. With this add
mode, it could be expected that each drop of organic solution may
disperse more easily into the aqueous phase before the gel phase for-
mation. Fig. 4 shows that, at the low concentration (57mg·g−1 solu-
tion), independent of W/IL ratio, the presence of ultrasound led to the
formation of smaller crystals (Fig. 5), with more uniform morphologies
and more deﬁned crystals edges. The same rod-shape was observed.
Whatever W/IL mass ratio, the mean volume diameter D4,3 varied
from about 7.0 (0W) to 2.0 µm (40W). The residual solvent decreased
slightly with ultrasound, i.e., from 984 ppm to 933 ppm with high W/IL
ratio and from 1265 ppm to 956 ppm with low W/IL ratio.
Experiments with ultrasound were also performed to study the in-
ﬂuence of drug solution concentration. As shown in Fig. 6(a), the par-
ticle size distributions with 159, 57 and 29mg·g−1 solution were si-
milar in volume. The size distributions in number indicate that the
intensity of the ﬁrst peak (< 1 μm) is greater for the crystals prepared
with 159mg·g−1 solution (Fig. 6(b)). These results are conﬁrmed by
SEM images (Fig. 7). Nucleation rate is favored with a high drug
Fig. 2. Particle size distribution of recrystallized LASSBio-294 by quick addi-
tion.
solution concentration and smaller crystals are formed. However, sol-
vent residual amounts increased with drug solution concentration as
shown in Table 1 (887 ppm at 29mg·g−1 solution, 956 ppm at
57mg·g−1 solution and 13273 ppm at 159mg·g−1 solution).
Some experiments were also carried to verify the inﬂuence of the
ultrasound’s power. The particle size distributions (Fig. 8) show that
smaller crystals were generated when a power higher than 20W is
applied (D4,3≤ 2.4 µm) (Table 1). In silent condition or with 10W the
percentage of agglomerates is higher (D4,3≥ 6.8 µm). In silent condi-
tion or with 10W, the percentage of agglomerates was higher
(D4,3≥ 6.8 µm). At 10W, the cavitation bubbles seemed to induce the
gelation of the system, leading to a higher residual solvent amount
(9517 ppm) and less deﬁned crystals edges, compared with results
without ultrasound or with power> 20W. The increase of power ul-
trasound produced more uniform crystals and no heterogeneity of
crystals habit (plates and sticks) was observed at 40W (Fig. 9).
Fig. 3. SEM images of recrystallized LASSBio-294 obtained by quick addition. (a) 159mg·g−1 solution and 13.9W/IL ratio (experiment 1); (b) 159mg·g−1 solution
and 14.9W/IL ratio with US (experiment 2); (c) 159mg·g−1 solution and 3.7W/IL ratio (experiment 3); (d) 159mg·g−1 solution and 3.9W/IL ratio (experiment 4);
(e) 57mg·g−1 solution and 4.7W/IL ratio (experiment 5); (f) 57mg·g−1 solution and 4.7W/IL ratio with US (experiment 6).
Fig. 4. Particle size distribution of recrystallized LASSBio-294 by dropwise
addition.
3.3. Eﬀect of crystals washing method
From solid characterization by ion chromatography, it could be
conﬁrmed that the new washing methods investigated resulted in a
successful reduction of residual solvent amounts in LASSBio-294 crys-
tals. Reductions in residual solvent from 18240 ppm (Method 1) to
2656 ppm (Method 3) and to 1503 ppm (Method 2) were detected. In
methods 2 and 3, the higher water amount probably removed the “gel”
formed by massive nucleation on the crystals surface. However, Fig. 10
shows that the morphologies of the crystals were modiﬁed by the dif-
ferent washing processes.
3.4. Eﬀect of drying process on particle size and speciﬁc surface area
(TBET) of crystals
The agglomeration of the crystals observed on the SEM images
could be occurred during the synthesis in the stirred tank and/or during
the drying process. The mean diameter of crystal particles dried in an
oven remained almost unchanged for all experiments [12]. During
drying, the “crystals agglomerates” already formed during the crystal-
lization process are agglomerated again. Spray drying was utilized
aiming to reduce this second agglomeration. Whatever the mixing mode
used, the crystals dried by spray drying were smaller than those dried in
an oven (Figs. 11 and 12) with decreased D4,3 and D3,2 values and
higher speciﬁc surface area (Table 2). Compared to oven-dried crystals,
the add mode (quick or dropwise) seemed to have less inﬂuence on the
mean particle size of spray-dried crystals. Spray-dried crystals gener-
ated by quick addition presented higher speciﬁc surface areas.
3.5. XRD analysis
XRD analysis were performed to study the eﬀect of the antisolvent
crystallization on the crystallinity of LASSBio-294 crystals. Changes on
Fig. 5. SEM images of the recrystallized LASSBio-294 with low concentration (57mg·g−1 solution) and dropwise injection of the solution into reactor. (a) 13.3W/IL
ratio without US; (b) 13.1W/IL ratio with US; (c) 4.6W/IL ratio without US and (d) 4.6W/IL ratio with US.
Fig. 6. Particles size distribution (a) in volume and (b) in number of re-
crystallized LASSBio-294 with diﬀerent drug solution concentrations by drop-
wise addition.
drug crystallinity by antisolvent crystallization has already been de-
scribed [24,25]. Other studies showed that the antisolvent crystal-
lization process using ionic liquids as solvent involved the formation of
amorphous particles [15] or the development of new polymorphs
[16,17]. In our study, the recrystallized LASSBio-294 exhibited the
same crystalline peaks of the raw drug crystals (Fig. 13). However, the
XRD patterns indicated changes in peaks intensities, mainly at 24.59,
25.19 and 26.54° in 2θ. This behavior is probably related to a change in
the orientation and morphologies of the crystals and the reduction of
the particle size.
4. Dissolution studies
4.1. Dissolution experiments
The dissolution proﬁles of LASSBio-294 recrystallized under dif-
ferent crystallization conditions and oven-dried are shown in Fig. 14.
The recrystallized LASSBio-294 dissolved slower than the raw LASSBio-
294. For example, after 30min, 41% of the recrystallized drug (Ex-
periment 9) and 75% of the original crystals are dissolved. As already
discussed, LASSBio-294 is very slightly soluble in water. Its solubility in
aqueous medium with SDS 0.5% increases due to the formation of
surfactant micelles and micellar solubilization of the drug. Further-
more, the presence of the surfactant reduces the solid-liquid interfacial
tension and increases wettability of the crystals LASSBio-294. These
eﬀects enhanced the dissolution of the LASSBio-294, explaining the
higher dissolution rate of the original crystals. The results also showed
that the application of ultrasound generated LASSBio-294 crystals with
slower dissolution. However, when powders are examined in SEM
(Fig. 15), it appears that the dissolution of recrystallized LASSBio-294
depended on both factors, crystals morphology and agglomeration/
aggregation states: Dropwise without US (Experiment 9) > Quick
without US (Experiment 5) > Quick with US (Experiment
6) > Dropwise with US (Experiment 10) (faster dissolution from less to
more compact). No relationship was observed between the dissolution
rate, residual solvent and mean size of the dry crystals. The dissolution
proﬁles of the crystals obtained by spray drying are shown in Fig. 16. As
described above, the recrystallized LASSBio-294 dissolved slower than
the raw LASSBio-294. However, spray-drying crystals dissolved more
rapidly than those oven-dried (Table 3). Spray drying favored the for-
mation of smaller agglomerates, which disaggregated easier when dis-
persed in the dissolution medium.
4.2. Kinetic assessment and release mechanisms
The experimental kinetic dissolution proﬁles for recrystallized
LASSBio-294 seemed to be driven by a phenomenon of diﬀusion lim-
iting the crystals dissolution. Although, spray drying increased the
dissolution of the crystals, diﬀusion probably remained the mechanism
limiting the crystals dissolution. To verify this statement, the cumula-
tive drug release from recrystallized LASSBio-294 was ﬁtted in Higuchi
Fig. 7. SEM images of ecrystallized LASSBio-294 by dropwise injection and
diﬀerent concentrations: (a) 159mg·g−1 solution (experiment 11), (b)
57mg·g−1 solution (experiment 10) and (c) 29mg·g−1 solution (experiment
12).
Fig. 8. Particles size distribution and SEM images of recrystallized LASSBio-294
with low concentration (57mg·g−1 solution) by dropwise addition of the so-
lution into reactor.
Fig. 9. SEM images of the recrystallized LASSBio-294 by dropwise addition. (a) 40W, experiment 10); (b) 30W, experiment 13; (c) 20W, experiment 14; (d) 10W,
experiment 15 and (e) 0W, experiment 9 (without ultrasound).
Fig. 10. SEM images of recrystallized LASSBio-294 by quick addition and diﬀerent washing methods. (a) Method 1, (b) Method 2 and (c) Method 3.
Fig. 11. SEM images of recrystallized LASSBio-294 by quick addition: eﬀect of drying process. Oven drying: (a) without and (b) with ultrasound; Spray drying: (c)
without and (d) with ultrasound.
Fig. 12. SEM images of recrystallized LASSBio-294 by dropwise addition: eﬀect of drying process. Oven drying: (a) without and (b) with ultrasound; Spray drying: (c)
without and (d) with ultrasound.
model =Q K t( )t H , which describe the drug release from matrix
system [26] and where Qt is the dissolved amount at the time, KH is the
constant Higuchi and t is the dissolution time.
The regression coeﬃcients (R2-values) generated following ﬁtting of
drug release data to the Higuchi model equation are summarized in
Table 4, conﬁrming that this model can well represent the dissolution
mechanism of recrystallized LASSBio-294 controlled by diﬀusion, re-
gardless of the crystals drying method used. Disintegration of growth
units was probably related to the structure of the agglomerates. The
greater agglomerates were compact, lowering diﬀusion of the disin-
tegrated units. Therefore, slower is the dissolution, which implies a
limited diﬀusion.
5. Conclusions
Antisolvent crystallization of LASSBio-294 was performed via ul-
trasonic process using 1-ethyl-3-methyl imidazolium methyl-phospho-
nate as solvent and water as antisolvent. Ultrasounds application
Table 2
Eﬀect of the drying method on the characteristics of LASSBio-294 crystals.
Oven drying Spray drying
Addition mode D4,3 (µm) D3,2 (µm) Speciﬁc surface (m2.g−1) D4,3 (µm) D3,2 (µm) Speciﬁc surface (m2.g−1)
Quick, without US 6.5 2.7 1.30 ± 0.02 4.8 1.5 7.40 ± 0.09
Quick, with US 7.0 2.1 3.45 ± 0.03 4.2 1.3 7.53 ± 0.06
Dropwise, without US 9.5 3.1 1.13 ± 0.08 4.6 1.7 2.72 ± 0.14
Dropwise, with US 11.0 2.6 3.12 ± 0.03 3.6 1.4 5.78 ± 0.06
Fig. 13. XRD patterns of LASSBio-294 under diﬀerent conditions. (a) raw LASSBio-294; (b) quick (experiment 5) and (c) dropwise addition (experiment 9).
Fig. 14. Dissolution rate proﬁles of LASSBio-294 recrystallized under diﬀerent crystallization conditions (n=3) and oven-dried.
allowed to modify the crystals properties and promoted the formation
of the small crystals in some conditions operating, but it did not avoid
crystals agglomeration. A phenomenon of “gelation” was observed at
high supersaturation conditions. The system seemed to freeze and
structures without deﬁned edges and rich in residual solvent were ob-
served. With quick addition, high drug solution concentration and W/IL
ratio, smaller crystals with higher residual IL are formed compared to
the conventional procedure. With dropwise addition and low drug so-
lution concentration, regardless of W/IL ratio, the presence of ultra-
sound led to the formation of smaller crystals, with more uniform
morphologies, more deﬁned crystals edges and less residual IL. The
dissolution rate was not enhanced by the reduction of the drug particle
size, but it was aﬀected by the physical structure of the agglomerates.
Spray drying process reduced this agglomeration and improved the
dissolution rate, which is controlled by diﬀusion (Higuchi model), re-
gardless of the crystals drying method.
To conclude, the antisolvent crystallization method using ionic li-
quids as solvent can be an alternative for recrystallization of drugs
poorly soluble in organic solvents, however it presents the following
critical aspects that must be considered: deﬁnition of good mixing
Fig. 15. SEM images of recrystallized LASSBio-294. (a) Dropwise addition without US (Experiment 9); (b) Quick addition without US (Experiment 5); (c) Quick
addition with US (Experiment 6) and (d) Dropwise addition with US (Experiment 10).
Fig. 16. Dissolution rate proﬁles of LASSBio-294 recrystallized under diﬀerent crystallization conditions (n= 3) and dried by spray drying.
conditions and diﬃculties of removal of the residual solvent from the
crystal’s structures. Finally, residual amounts of ionic liquid can change
crystals morphologies.
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Table 3
Eﬀect of drying process on dissolution percentage of the recrystallized LASSBio-
294.
Oven drying Spray drying
Experiment Qt (%) Qt (%)
5min 30min 5min 30min
Quick without
US
16.14 ± 6.45 34.32 ± 3.52 21.24 ± 3.76 42.74 ± 4.95
Quick with US 10.66 ± 1.98 26.77 ± 2.77 31.62 ± 5.85 55.79 ± 4.23
Dropwise
without
US
18.04 ± 4.14 41.15 ± 3.17 29.03 ± 2.14 47.98 ± 2.45
Dropwise with
US
9.23 ± 2.26 23.12 ± 0.88 27.97 ± 1.24 48.56 ± 3.51
Table 4
Dissolution rate constant and R2 obtained from the application of Higuchi
model for recrystallized LASSBio-294.
Experiment Higuchi
KH R2
Raw LASSBio-294 9.6195 0.9074
Oven drying
Quick without US 5.6132 0.9991
Quick with US 4.4359 0.9980
Dropwise without US 6.4720 0.9967
Dropwise with US 3.8677 0.9984
Spray drying
Quick without US 5.5442 0.9876
Quick with US 6.5076 0.9800
Dropwise without US 5.1109 0.9956
Dropwise with US 5.2646 0.9907
